Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,659
archived clinical trials in
Metabolic

Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)
Status: Enrolling
Updated:  12/11/2015
Clinical Research Facility
mi
from
Orangeburg, SC
Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)
Status: Enrolling
Updated: 12/11/2015
Clinical Research Facility
mi
from
Orangeburg, SC
Click here to add this to my saved trials
Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)
Status: Enrolling
Updated:  12/11/2015
Clinical Research Facility
mi
from
Bristol, TN
Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)
Status: Enrolling
Updated: 12/11/2015
Clinical Research Facility
mi
from
Bristol, TN
Click here to add this to my saved trials
Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)
Status: Enrolling
Updated:  12/11/2015
Clinical Research Facility
mi
from
Houston, TX
Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)
Status: Enrolling
Updated: 12/11/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)
Status: Enrolling
Updated:  12/11/2015
Clinical Research Facility
mi
from
Katy, TX
Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)
Status: Enrolling
Updated: 12/11/2015
Clinical Research Facility
mi
from
Katy, TX
Click here to add this to my saved trials
Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)
Status: Enrolling
Updated:  12/11/2015
Research Site
mi
from
Chocoutimi,
Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)
Status: Enrolling
Updated: 12/11/2015
Research Site
mi
from
Chocoutimi,
Click here to add this to my saved trials
Screening To Obviate Preterm Birth
Screening To Obviate Preterm Birth
Status: Enrolling
Updated:  12/22/2015
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Screening To Obviate Preterm Birth
Screening To Obviate Preterm Birth
Status: Enrolling
Updated: 12/22/2015
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome
A Randomized, Double-Blind, Pilot Study of the Safety and Physiological Effects of Two Doses of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Status: Enrolling
Updated:  12/24/2015
Clinical Research Facility
mi
from
New York, NY
Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome
A Randomized, Double-Blind, Pilot Study of the Safety and Physiological Effects of Two Doses of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Status: Enrolling
Updated: 12/24/2015
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome
A Randomized, Double-Blind, Pilot Study of the Safety and Physiological Effects of Two Doses of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Status: Enrolling
Updated:  12/24/2015
Clinical Research Facility
mi
from
Oakland, CA
Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome
A Randomized, Double-Blind, Pilot Study of the Safety and Physiological Effects of Two Doses of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Status: Enrolling
Updated: 12/24/2015
Clinical Research Facility
mi
from
Oakland, CA
Click here to add this to my saved trials
Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome
A Randomized, Double-Blind, Pilot Study of the Safety and Physiological Effects of Two Doses of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Status: Enrolling
Updated:  12/24/2015
Clinical Research Facility
mi
from
Chicago, IL
Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome
A Randomized, Double-Blind, Pilot Study of the Safety and Physiological Effects of Two Doses of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Status: Enrolling
Updated: 12/24/2015
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome
A Randomized, Double-Blind, Pilot Study of the Safety and Physiological Effects of Two Doses of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Status: Enrolling
Updated:  12/24/2015
Clinical Research Facility
mi
from
Houston, TX
Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome
A Randomized, Double-Blind, Pilot Study of the Safety and Physiological Effects of Two Doses of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Status: Enrolling
Updated: 12/24/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome
A Randomized, Double-Blind, Pilot Study of the Safety and Physiological Effects of Two Doses of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Status: Enrolling
Updated:  12/24/2015
mi
from
Calgary,
Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome
A Randomized, Double-Blind, Pilot Study of the Safety and Physiological Effects of Two Doses of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Status: Enrolling
Updated: 12/24/2015
mi
from
Calgary,
Click here to add this to my saved trials
Androgenetic Alopecia in Fabry Disease
Androgenetic Alopecia in Fabry Disease
Status: Enrolling
Updated:  1/12/2016
Baylor University Medical Center
mi
from
Dallas, TX
Androgenetic Alopecia in Fabry Disease
Androgenetic Alopecia in Fabry Disease
Status: Enrolling
Updated: 1/12/2016
Baylor University Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Mexiletine for the Treatment of Muscle Cramps in ALS
Mexiletine for the Treatment of Muscle Cramps in ALS
Status: Enrolling
Updated:  1/18/2016
UCD Telehealth Network - Lake Almanor Clinic
mi
from
Chester, CA
Mexiletine for the Treatment of Muscle Cramps in ALS
Mexiletine for the Treatment of Muscle Cramps in ALS
Status: Enrolling
Updated: 1/18/2016
UCD Telehealth Network - Lake Almanor Clinic
mi
from
Chester, CA
Click here to add this to my saved trials
Mexiletine for the Treatment of Muscle Cramps in ALS
Mexiletine for the Treatment of Muscle Cramps in ALS
Status: Enrolling
Updated:  1/18/2016
UCSD Department of Neurosciences ALS Clinical Trials (ACT) Program
mi
from
La Jolla, CA
Mexiletine for the Treatment of Muscle Cramps in ALS
Mexiletine for the Treatment of Muscle Cramps in ALS
Status: Enrolling
Updated: 1/18/2016
UCSD Department of Neurosciences ALS Clinical Trials (ACT) Program
mi
from
La Jolla, CA
Click here to add this to my saved trials
Mexiletine for the Treatment of Muscle Cramps in ALS
Mexiletine for the Treatment of Muscle Cramps in ALS
Status: Enrolling
Updated:  1/18/2016
UCLA Neuromuscular Research Program
mi
from
Los Angeles, CA
Mexiletine for the Treatment of Muscle Cramps in ALS
Mexiletine for the Treatment of Muscle Cramps in ALS
Status: Enrolling
Updated: 1/18/2016
UCLA Neuromuscular Research Program
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Mexiletine for the Treatment of Muscle Cramps in ALS
Mexiletine for the Treatment of Muscle Cramps in ALS
Status: Enrolling
Updated:  1/18/2016
UCD Telehealth Network
mi
from
One hundred sites, CA
Mexiletine for the Treatment of Muscle Cramps in ALS
Mexiletine for the Treatment of Muscle Cramps in ALS
Status: Enrolling
Updated: 1/18/2016
UCD Telehealth Network
mi
from
One hundred sites, CA
Click here to add this to my saved trials
Mexiletine for the Treatment of Muscle Cramps in ALS
Mexiletine for the Treatment of Muscle Cramps in ALS
Status: Enrolling
Updated:  1/18/2016
UC Irvine Health ALS & Neuromuscular Center
mi
from
Orange, CA
Mexiletine for the Treatment of Muscle Cramps in ALS
Mexiletine for the Treatment of Muscle Cramps in ALS
Status: Enrolling
Updated: 1/18/2016
UC Irvine Health ALS & Neuromuscular Center
mi
from
Orange, CA
Click here to add this to my saved trials
Mexiletine for the Treatment of Muscle Cramps in ALS
Mexiletine for the Treatment of Muscle Cramps in ALS
Status: Enrolling
Updated:  1/18/2016
UC, Davis Medical Center ALS Clinic
mi
from
Sacramento, CA
Mexiletine for the Treatment of Muscle Cramps in ALS
Mexiletine for the Treatment of Muscle Cramps in ALS
Status: Enrolling
Updated: 1/18/2016
UC, Davis Medical Center ALS Clinic
mi
from
Sacramento, CA
Click here to add this to my saved trials
A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I
A Study of Intrathecal Enzyme Replacement for Cognitive Decline in Mucopolysaccharidosis I
Status: Enrolling
Updated:  1/22/2016
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I
A Study of Intrathecal Enzyme Replacement for Cognitive Decline in Mucopolysaccharidosis I
Status: Enrolling
Updated: 1/22/2016
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I
A Study of Intrathecal Enzyme Replacement for Cognitive Decline in Mucopolysaccharidosis I
Status: Enrolling
Updated:  1/22/2016
Los Angeles Biomedical Institute at Harbor-UCLA
mi
from
Torrance, CA
A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I
A Study of Intrathecal Enzyme Replacement for Cognitive Decline in Mucopolysaccharidosis I
Status: Enrolling
Updated: 1/22/2016
Los Angeles Biomedical Institute at Harbor-UCLA
mi
from
Torrance, CA
Click here to add this to my saved trials
A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I
A Study of Intrathecal Enzyme Replacement for Cognitive Decline in Mucopolysaccharidosis I
Status: Enrolling
Updated:  1/22/2016
Univ of Minnesota
mi
from
Minneapolis, MN
A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I
A Study of Intrathecal Enzyme Replacement for Cognitive Decline in Mucopolysaccharidosis I
Status: Enrolling
Updated: 1/22/2016
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Reexamining Hypotonic Intravenous Fluid Use
Reexamining Hypotonic Intravenous Fluid Use in Pediatric Patients With Gastroenteritis.
Status: Enrolling
Updated:  1/26/2016
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Reexamining Hypotonic Intravenous Fluid Use
Reexamining Hypotonic Intravenous Fluid Use in Pediatric Patients With Gastroenteritis.
Status: Enrolling
Updated: 1/26/2016
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol®) in Pediatric Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center, Dose-Titration Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol®) in Pediatric Subjects With Euvolemic or Hypervolemic Hyponatremia
Status: Enrolling
Updated:  2/1/2016
Children's Hospital New York-Presbyterian
mi
from
New York, NY
A Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol®) in Pediatric Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center, Dose-Titration Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol®) in Pediatric Subjects With Euvolemic or Hypervolemic Hyponatremia
Status: Enrolling
Updated: 2/1/2016
Children's Hospital New York-Presbyterian
mi
from
New York, NY
Click here to add this to my saved trials
A Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol®) in Pediatric Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center, Dose-Titration Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol®) in Pediatric Subjects With Euvolemic or Hypervolemic Hyponatremia
Status: Enrolling
Updated:  2/1/2016
Fundación Cardioinfantil - Instituto Cardiológico
mi
from
Bogota,
A Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol®) in Pediatric Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center, Dose-Titration Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol®) in Pediatric Subjects With Euvolemic or Hypervolemic Hyponatremia
Status: Enrolling
Updated: 2/1/2016
Fundación Cardioinfantil - Instituto Cardiológico
mi
from
Bogota,
Click here to add this to my saved trials
Effects of Acipimox on Mitochondrial Function in Obesity
The Effects of Short Term Acipimox Treatment on Skeletal Muscle Phosphocreatine Recovery in Obesity
Status: Enrolling
Updated:  2/2/2016
Massachusetts General Hospital
mi
from
Boston, MA
Effects of Acipimox on Mitochondrial Function in Obesity
The Effects of Short Term Acipimox Treatment on Skeletal Muscle Phosphocreatine Recovery in Obesity
Status: Enrolling
Updated: 2/2/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Effects of Lovaza on High Density Lipoprotein (HDL) Composition and Function in Hypertriglyceridemia
Effects of Lovaza Monotherapy vs. Placebo on Composition and Function of HDL and Other Lipoproteins, and on Other Lipid-Related Parameters
Status: Enrolling
Updated:  2/4/2016
University of Utah
mi
from
Salt Lake City, UT
Effects of Lovaza on High Density Lipoprotein (HDL) Composition and Function in Hypertriglyceridemia
Effects of Lovaza Monotherapy vs. Placebo on Composition and Function of HDL and Other Lipoproteins, and on Other Lipid-Related Parameters
Status: Enrolling
Updated: 2/4/2016
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Administration of IV Laronidase Post Bone Marrow Transplant in Hurler
Pilot Study of Administration of Intravenous Laronidase Following Allogeneic Transplantation for Hurler Syndrome
Status: Enrolling
Updated:  2/23/2016
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Administration of IV Laronidase Post Bone Marrow Transplant in Hurler
Pilot Study of Administration of Intravenous Laronidase Following Allogeneic Transplantation for Hurler Syndrome
Status: Enrolling
Updated: 2/23/2016
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia
Diet/Exercise, Niacin, Fenofibrate for HIV Lipodystrophy
Status: Enrolling
Updated:  2/25/2016
Baylor College of Medicine
mi
from
Houston, TX
Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia
Diet/Exercise, Niacin, Fenofibrate for HIV Lipodystrophy
Status: Enrolling
Updated: 2/25/2016
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia
Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia
Status: Enrolling
Updated:  3/14/2016
Massachusetts General Hospital
mi
from
Boston, MA
Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia
Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia
Status: Enrolling
Updated: 3/14/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy of LCQ908 on Cardiovascular Risk
A Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy of LCQ908 on Cardiovascular Risk
Status: Enrolling
Updated:  3/16/2016
Novartis Investigative Site
mi
from
Pasadena, CA
Efficacy of LCQ908 on Cardiovascular Risk
A Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy of LCQ908 on Cardiovascular Risk
Status: Enrolling
Updated: 3/16/2016
Novartis Investigative Site
mi
from
Pasadena, CA
Click here to add this to my saved trials
Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry Disease
A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Enzyme Replacement Therapy (ERT) Treatment-naïve Adult Male Patients Diagnosed With Fabry Disease
Status: Enrolling
Updated:  3/25/2016
Clinical Research Facility
mi
from
Atlanta, GA
Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry Disease
A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Enzyme Replacement Therapy (ERT) Treatment-naïve Adult Male Patients Diagnosed With Fabry Disease
Status: Enrolling
Updated: 3/25/2016
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry Disease
A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Enzyme Replacement Therapy (ERT) Treatment-naïve Adult Male Patients Diagnosed With Fabry Disease
Status: Enrolling
Updated:  3/25/2016
Clinical Research Facility
mi
from
Cincinnati, OH
Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry Disease
A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Enzyme Replacement Therapy (ERT) Treatment-naïve Adult Male Patients Diagnosed With Fabry Disease
Status: Enrolling
Updated: 3/25/2016
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry Disease
A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Enzyme Replacement Therapy (ERT) Treatment-naïve Adult Male Patients Diagnosed With Fabry Disease
Status: Enrolling
Updated:  3/25/2016
Clinical Research Facility
mi
from
Fairfax, VA
Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry Disease
A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Enzyme Replacement Therapy (ERT) Treatment-naïve Adult Male Patients Diagnosed With Fabry Disease
Status: Enrolling
Updated: 3/25/2016
Clinical Research Facility
mi
from
Fairfax, VA
Click here to add this to my saved trials
Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry Disease
A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Enzyme Replacement Therapy (ERT) Treatment-naïve Adult Male Patients Diagnosed With Fabry Disease
Status: Enrolling
Updated:  3/25/2016
Investigational Site Number 203001
mi
from
Praha 2,
Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry Disease
A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Enzyme Replacement Therapy (ERT) Treatment-naïve Adult Male Patients Diagnosed With Fabry Disease
Status: Enrolling
Updated: 3/25/2016
Investigational Site Number 203001
mi
from
Praha 2,
Click here to add this to my saved trials
Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients
A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 12 Weeks to Adult Fabry Patients
Status: Enrolling
Updated:  4/18/2016
UC Davis Medical Center, MIND Institute Department of Pediatrics, Section of Genetics
mi
from
Sacramento, CA
Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients
A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 12 Weeks to Adult Fabry Patients
Status: Enrolling
Updated: 4/18/2016
UC Davis Medical Center, MIND Institute Department of Pediatrics, Section of Genetics
mi
from
Sacramento, CA
Click here to add this to my saved trials
Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients
A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 12 Weeks to Adult Fabry Patients
Status: Enrolling
Updated:  4/18/2016
Department of Human Genetics, Emory University School of Medicine
mi
from
Atlanta, GA
Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients
A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 12 Weeks to Adult Fabry Patients
Status: Enrolling
Updated: 4/18/2016
Department of Human Genetics, Emory University School of Medicine
mi
from
Atlanta, GA
Click here to add this to my saved trials
Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients
A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 12 Weeks to Adult Fabry Patients
Status: Enrolling
Updated:  4/18/2016
University of Iowa Health Clinics
mi
from
Iowa City, IA
Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients
A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 12 Weeks to Adult Fabry Patients
Status: Enrolling
Updated: 4/18/2016
University of Iowa Health Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients
A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 12 Weeks to Adult Fabry Patients
Status: Enrolling
Updated:  4/18/2016
University of Kansas Medical Center
mi
from
Kansas City, KA
Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients
A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 12 Weeks to Adult Fabry Patients
Status: Enrolling
Updated: 4/18/2016
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients
A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 12 Weeks to Adult Fabry Patients
Status: Enrolling
Updated:  4/18/2016
Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients
A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 12 Weeks to Adult Fabry Patients
Status: Enrolling
Updated: 4/18/2016
Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients
A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 12 Weeks to Adult Fabry Patients
Status: Enrolling
Updated:  4/18/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients
A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 12 Weeks to Adult Fabry Patients
Status: Enrolling
Updated: 4/18/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients
A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 12 Weeks to Adult Fabry Patients
Status: Enrolling
Updated:  4/18/2016
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients
A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 12 Weeks to Adult Fabry Patients
Status: Enrolling
Updated: 4/18/2016
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients
A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 12 Weeks to Adult Fabry Patients
Status: Enrolling
Updated:  4/18/2016
Research Baylor Institute of Metabolic Disease
mi
from
Dallas, TX
Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients
A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 12 Weeks to Adult Fabry Patients
Status: Enrolling
Updated: 4/18/2016
Research Baylor Institute of Metabolic Disease
mi
from
Dallas, TX
Click here to add this to my saved trials
Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients
A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 12 Weeks to Adult Fabry Patients
Status: Enrolling
Updated:  4/18/2016
O&O Alpan
mi
from
Fairfax, VA
Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients
A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 12 Weeks to Adult Fabry Patients
Status: Enrolling
Updated: 4/18/2016
O&O Alpan
mi
from
Fairfax, VA
Click here to add this to my saved trials
Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients
A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 12 Weeks to Adult Fabry Patients
Status: Enrolling
Updated:  4/18/2016
Royal Melbourne Hospital
mi
from
Victoria,
Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients
A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 12 Weeks to Adult Fabry Patients
Status: Enrolling
Updated: 4/18/2016
Royal Melbourne Hospital
mi
from
Victoria,
Click here to add this to my saved trials
Calcitonin for Treating X-linked Hypophosphatemia
Calcitonin for Treating X-linked Hypophosphatemia
Status: Enrolling
Updated:  5/24/2016
Yale School of Medicine
mi
from
New Haven, CT
Calcitonin for Treating X-linked Hypophosphatemia
Calcitonin for Treating X-linked Hypophosphatemia
Status: Enrolling
Updated: 5/24/2016
Yale School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
A Cross-sectional Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
Status: Enrolling
Updated:  7/6/2016
Clinical Research Facility
mi
from
Decatur, GA
A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
A Cross-sectional Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
Status: Enrolling
Updated: 7/6/2016
Clinical Research Facility
mi
from
Decatur, GA
Click here to add this to my saved trials
A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
A Cross-sectional Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
Status: Enrolling
Updated:  7/6/2016
Clinical Research Facility
mi
from
Cincinnati, OH
A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
A Cross-sectional Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
Status: Enrolling
Updated: 7/6/2016
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
A Cross-sectional Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
Status: Enrolling
Updated:  7/6/2016
Clinical Research Facility
mi
from
Fairfax, VA
A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
A Cross-sectional Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
Status: Enrolling
Updated: 7/6/2016
Clinical Research Facility
mi
from
Fairfax, VA
Click here to add this to my saved trials
A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
A Cross-sectional Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
Status: Enrolling
Updated:  7/6/2016
Clinical Research Facility
mi
from
Milwaukee, WI
A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
A Cross-sectional Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
Status: Enrolling
Updated: 7/6/2016
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
A Cross-sectional Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
Status: Enrolling
Updated:  7/6/2016
Investigational Site Number 032001
mi
from
Capital Federal,
A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
A Cross-sectional Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
Status: Enrolling
Updated: 7/6/2016
Investigational Site Number 032001
mi
from
Capital Federal,
Click here to add this to my saved trials